11 assets in Hyperlipidemia

Therapeutic assets addressing Hyperlipidemia, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Rosuvastatin Hyperlipidemia	Nanjing First Hospital, Nanjing Medical University	P4	BBB (77)
Ezetimibe Hyperlipidemia	NewAmsterdam Pharma	P4	BBB (74)
Inclisiran Hyperlipidemia	University of California, San Diego	P4	BB (65)
Obicetrapib Hyperlipidemia	NewAmsterdam Pharma	P3	B (60)
Gly-Low Hyperlipidemia	Hoskinson Health and Wellness Clinic	Early P1	CC (43)
Apple Cider Vinegar Hyperlipidemia	Western University	Early P1	C (39)
Metformin Hyperlipidemia	Mais Qais Hbeeb	N/A	D (30)
Sitagliptin Hyperlipidemia	Mais Qais Hbeeb	N/A	D (30)
Rdx-002 Hyperlipidemia	Response Pharmaceuticals	P2	NR ()